Page last updated: 2024-12-08

1,3-dimethyl-2,4-dioxo-6-benzyl-1,2,3,4,5,6,7,8-octahydropyrimido(4,5-d)pyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

You're describing a compound with a rather complex name! Let's break it down:

**1,3-dimethyl-2,4-dioxo-6-benzyl-1,2,3,4,5,6,7,8-octahydropyrimido(4,5-d)pyrimidine**

* **1,3-dimethyl:** This indicates two methyl groups (CH3) are attached at positions 1 and 3 of the main ring structure.
* **2,4-dioxo:** This means there are two carbonyl groups (C=O) at positions 2 and 4 of the ring system.
* **6-benzyl:** A benzyl group (C6H5CH2-) is attached at position 6.
* **1,2,3,4,5,6,7,8-octahydropyrimido(4,5-d)pyrimidine:** This is the core structure. It's a fused ring system where a pyrimidine ring (a six-membered ring with two nitrogen atoms) is fused to a hexahydropyrimidine ring (a six-membered ring with two nitrogen atoms and four carbons). The (4,5-d) indicates how the pyrimidine ring is fused to the hexahydropyrimidine ring.

**Importance in Research**

This compound is likely an **analog of a known biomolecule** or a **potential drug candidate**. Its specific importance depends on the research area it's used in. Here's why compounds like this are important for research:

* **Drug Discovery:** By modifying existing molecules, researchers can potentially create new drugs with improved efficacy, fewer side effects, or better targeting abilities. The unique structure of this compound could make it a potential lead for various therapeutic applications.
* **Biological Studies:** This compound could be used to study the function of specific proteins or enzymes. By binding to a protein, it might modulate its activity, providing insights into biological pathways.
* **Materials Science:** The structural features of this compound might make it useful in material science applications like polymer chemistry or organic electronics.

**To understand its specific importance, you'll need more context. For example, is this compound:**

* **A known drug?**
* **A potential drug candidate?**
* **A molecule used in a specific biological study?**

Knowing this context will help determine why this compound is relevant to research.

1,3-dimethyl-2,4-dioxo-6-benzyl-1,2,3,4,5,6,7,8-octahydropyrimido(4,5-d)pyrimidine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID155675
MeSH IDM0091358

Synonyms (25)

Synonym
EU-0047218
6-benzyl-1,3-dimethyl-7,8-dihydro-5h-pyrimido[4,5-d]pyrimidine-2,4-dione
6-benzyl-1,3-dimethyl-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidine-2,4(1h,3h)-dione
nsc350009
nsc-350009
71803-56-0
mls003389347 ,
OPREA1_276129
dmdobohpp
STK041239
HMS1627O16
AKOS001505365
smr002049002
1,3-dimethyl-2,4-dioxo-6-benzyl-1,2,3,4,5,6,7,8-octahydropyrimido(4,5-d)pyrimidine
unii-3o0g0zu69f
pyrimido(4,5-d)pyrimidine-2,4(1h,3h)-dione, 5,6,7,8-tetrahydro-1,3-dimethyl-6-(phenylmethyl)-
nsc 350009
3o0g0zu69f ,
CCG-133487
DTXSID00222083
sr-01000505781
6-benzyl-1,3-dimethyl-1h,2h,3h,4h,5h,6h,7h,8h-[1,3]diazino[4,5-d]pyrimidine-2,4-dione
SR-01000505781-1
5,6,7,8-tetrahydro-1,3-dimethyl-6-(phenylmethyl)pyrimido(4,5-d)pyrimidine-2,4(1h,3h)-dione
bdpd
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's5 (55.56)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]